These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23333526)

  • 1. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis.
    Waidmann O; Brunner F; Herrmann E; Zeuzem S; Piiper A; Kronenberger B
    J Hepatol; 2013 May; 58(5):956-61. PubMed ID: 23333526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
    Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
    J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
    Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
    Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Serum Soluble CD163 in the Diagnosis, Risk of Bleeding, and Prognosis of Gastro-Esophageal Varices in Cirrhotic Patients.
    Fouad R; Hamza I; Khairy M; Elsharkawy M; Helmy AA
    J Interferon Cytokine Res; 2017 Mar; 37(3):112-118. PubMed ID: 28282272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection.
    Tornai T; Vitalis Z; Sipeki N; Dinya T; Tornai D; Antal-Szalmas P; Karanyi Z; Tornai I; Papp M
    Liver Int; 2016 Nov; 36(11):1628-1638. PubMed ID: 27031405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
    Møller HJ; Moestrup SK; Weis N; Wejse C; Nielsen H; Pedersen SS; Attermann J; Nexø E; Kronborg G
    Crit Care Med; 2006 Oct; 34(10):2561-6. PubMed ID: 16915112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined platelet count with sCD163 and genetic variants optimizes esophageal varices prediction in cirrhotic patients.
    Yang YY; Hou MC; Lin MW; Chen PH; Liao WC; Chu CJ; Lin HC
    J Gastroenterol Hepatol; 2013 Jan; 28(1):112-21. PubMed ID: 22849380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
    Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O
    J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS.
    Holland-Fischer P; Grønbæk H; Sandahl TD; Moestrup SK; Riggio O; Ridola L; Aagaard NK; Møller HJ; Vilstrup H
    Gut; 2011 Oct; 60(10):1389-93. PubMed ID: 21572121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
    Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
    Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble CD163 from activated macrophages predicts mortality in acute liver failure.
    Møller HJ; Grønbaek H; Schiødt FV; Holland-Fischer P; Schilsky M; Munoz S; Hassanein T; Lee WM;
    J Hepatol; 2007 Nov; 47(5):671-6. PubMed ID: 17629586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
    Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Usefulness of DeltaMELD/month for prediction of the mortality in the first episode of variceal bleeding patients with liver cirrhosis: comparison with CTP, MELD score and DeltaCTP/month].
    Bae WK; Lee JS; Kim NH; Kim KA; Moon YS; Oh MK
    Korean J Hepatol; 2007 Mar; 13(1):51-60. PubMed ID: 17380075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
    Kim MY; Baik SK; Suk KT; Yea CJ; Lee IY; Kim JW; Cha SH; Kim YJ; Um SH; Han KH
    Korean J Hepatol; 2008 Jun; 14(2):150-8. PubMed ID: 18617762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables.
    Eslam M; Ampuero J; Jover M; Abd-Elhalim H; Rincon D; Shatat M; Camacho I; Kamal A; Lo Iacono O; Nasr Z; Grande L; Banares R; Khattab MA; Romero-Gomez M
    Ann Hepatol; 2013; 12(4):588-98. PubMed ID: 23813137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.
    Andersen MN; Abildgaard N; Maniecki MB; Møller HJ; Andersen NF
    Eur J Haematol; 2014 Jul; 93(1):41-7. PubMed ID: 24612259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical illness-related corticosteroid insufficiency in cirrhotic patients with acute gastroesophageal variceal bleeding: risk factors and association with outcome*.
    Tsai MH; Huang HC; Peng YS; Chen YC; Tian YC; Yang CW; Lien JM; Fang JT; Wu CS; Lee FY
    Crit Care Med; 2014 Dec; 42(12):2546-55. PubMed ID: 25083978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.
    Turnes J; Garcia-Pagan JC; Abraldes JG; Hernandez-Guerra M; Dell'Era A; Bosch J
    Am J Gastroenterol; 2006 Mar; 101(3):506-12. PubMed ID: 16542287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
    Grønbæk H; Rødgaard-Hansen S; Aagaard NK; Arroyo V; Moestrup SK; Garcia E; Solà E; Domenicali M; Piano S; Vilstrup H; Møller HJ;
    J Hepatol; 2016 Apr; 64(4):813-22. PubMed ID: 26639396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
    Axelsson J; Møller HJ; Witasp A; Qureshi AR; Carrero JJ; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Moestrup SK; Stenvinkel P
    Am J Kidney Dis; 2006 Dec; 48(6):916-25. PubMed ID: 17162146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.